ZYCOS' Lead Drug Awarded Second Patent For Novel Treatment of HPV Infections

- Expands Patent Portfolio Position in Women's Health -



Apr 23, 2001, 01:00 ET from ZYCOS Inc.

    LEXINGTON, Mass., April 23 / PRNewswire Interactive News Release/ --
 ZYCOS Inc., a private biotechnology company, today announced that the United
 States Patent and Trademark Office has issued US Patent number No. 6,183,746,
 related to the Company's lead drug ZYC101a, a DNA-based product designed to
 boost the immune response against HPV infection.  ZYCOS' drug is currently in
 a multinational Phase II clinical trial in patients diagnosed with high-grade
 cervical dysplasia.
     Cervical dysplasia caused by HPV is a precancerous disease that affects
 nearly two million American women every year and costs $6 billion to diagnose
 and surgically treat in the U.S. alone.
     The new patent, which covers ZYCOS' unique DNA-based methods of inducing
 the immune response against diseases caused by HPV, is the second the Company
 has received relating to ZYC101a.  It is part of a family of divisional
 applications, including US Patent No. 6,013,258 that was granted for
 composition of matter.
     "This latest patent not only enhances the commercial profile of our
 HPV-specific product," explained Dr. Mary Lynne Hedley, Vice-President of
 Research at ZYCOS Inc., "it also reinforces the already strong foundation of
 interweaving technology patents which support ZYCOS' product portfolio."
     Dr. Mark Philip, President and CEO of ZYCOS Inc., stated, "ZYCOS continues
 to focus on accelerating products through the clinic and maximizing their
 commercial potential in the marketplace.  This product patent demonstrates the
 strong intellectual property position that ZYCOS can apply to both internal
 drug development programs and potential alliances with corporate partners who
 are interested in developing DNA drugs."
     ZYCOS' technology platform is comprised of a proprietary DNA expression
 vector to encode disease-specific genes and a complementary microsphere system
 for targeted drug delivery.  ZYCOS also possesses an antigen discovery system
 based on advanced microchemistries and state-of-the-art mass spectrometry to
 accelerate drug development.  ZYCOS is using its technologies to build a broad
 pipeline of DNA-based products that are designed to enhance the body's natural
 response against specific diseases.  The Company is also developing ZYC200 to
 treat inflammatory conditions and ZYC300 for cancer treatments.
 
      Additional patent information can be found at
      http://zycos.com/m1_tech_pats.html.
 
     ZYCOS (http://www.zycos.com) is a privately held company located in
 Lexington, Massachusetts. ZYCOS' core technology platform has led to the
 development of a new category of therapeutic medicines targeting multi-billion
 dollar markets in the areas of cancer, viral infections and autoimmune
 disease.  ZYCOS' discovery technology enables the rapid discovery of
 disease-specific antigens.  The Company has also developed novel systems for
 DNA expression and DNA drug delivery. ZYCOS' first product candidate, ZYC101a
 is designed to treat cervical infections associated with the human
 papillomavirus and is currently in Phase II clinical studies.
 
     This press release contains, in addition to historical information,
 forward-looking statements that involve risks and uncertainties.  Actual
 results may differ materially from those currently anticipated by ZYCOS.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X48492185
 
 

SOURCE ZYCOS Inc.
    LEXINGTON, Mass., April 23 / PRNewswire Interactive News Release/ --
 ZYCOS Inc., a private biotechnology company, today announced that the United
 States Patent and Trademark Office has issued US Patent number No. 6,183,746,
 related to the Company's lead drug ZYC101a, a DNA-based product designed to
 boost the immune response against HPV infection.  ZYCOS' drug is currently in
 a multinational Phase II clinical trial in patients diagnosed with high-grade
 cervical dysplasia.
     Cervical dysplasia caused by HPV is a precancerous disease that affects
 nearly two million American women every year and costs $6 billion to diagnose
 and surgically treat in the U.S. alone.
     The new patent, which covers ZYCOS' unique DNA-based methods of inducing
 the immune response against diseases caused by HPV, is the second the Company
 has received relating to ZYC101a.  It is part of a family of divisional
 applications, including US Patent No. 6,013,258 that was granted for
 composition of matter.
     "This latest patent not only enhances the commercial profile of our
 HPV-specific product," explained Dr. Mary Lynne Hedley, Vice-President of
 Research at ZYCOS Inc., "it also reinforces the already strong foundation of
 interweaving technology patents which support ZYCOS' product portfolio."
     Dr. Mark Philip, President and CEO of ZYCOS Inc., stated, "ZYCOS continues
 to focus on accelerating products through the clinic and maximizing their
 commercial potential in the marketplace.  This product patent demonstrates the
 strong intellectual property position that ZYCOS can apply to both internal
 drug development programs and potential alliances with corporate partners who
 are interested in developing DNA drugs."
     ZYCOS' technology platform is comprised of a proprietary DNA expression
 vector to encode disease-specific genes and a complementary microsphere system
 for targeted drug delivery.  ZYCOS also possesses an antigen discovery system
 based on advanced microchemistries and state-of-the-art mass spectrometry to
 accelerate drug development.  ZYCOS is using its technologies to build a broad
 pipeline of DNA-based products that are designed to enhance the body's natural
 response against specific diseases.  The Company is also developing ZYC200 to
 treat inflammatory conditions and ZYC300 for cancer treatments.
 
      Additional patent information can be found at
      http://zycos.com/m1_tech_pats.html.
 
     ZYCOS (http://www.zycos.com) is a privately held company located in
 Lexington, Massachusetts. ZYCOS' core technology platform has led to the
 development of a new category of therapeutic medicines targeting multi-billion
 dollar markets in the areas of cancer, viral infections and autoimmune
 disease.  ZYCOS' discovery technology enables the rapid discovery of
 disease-specific antigens.  The Company has also developed novel systems for
 DNA expression and DNA drug delivery. ZYCOS' first product candidate, ZYC101a
 is designed to treat cervical infections associated with the human
 papillomavirus and is currently in Phase II clinical studies.
 
     This press release contains, in addition to historical information,
 forward-looking statements that involve risks and uncertainties.  Actual
 results may differ materially from those currently anticipated by ZYCOS.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X48492185
 
 SOURCE  ZYCOS Inc.